Next Article in Journal
Infection Control in the Era of COVID-19: A Narrative Review
Next Article in Special Issue
Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis
Previous Article in Journal
Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study
Previous Article in Special Issue
The Epistatic Landscape of Antibiotic Resistance of Different Clades of Mycobacterium tuberculosis
 
 
Article

Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow

1
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
2
The Moscow Research and Clinical Center for Tuberculosis Control, Moscow Government Health Department, 107014 Moscow, Russia
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(10), 1243; https://doi.org/10.3390/antibiotics10101243
Received: 9 September 2021 / Revised: 6 October 2021 / Accepted: 11 October 2021 / Published: 13 October 2021
Background: Linezolid, bedaquiline, and newer fluoroquinolones are currently placed as priority Group A drugs for the treatment of drug-resistant tuberculosis. The number of reported linezolid-resistant clinical strains is still low, and the correlation of molecular determinants with phenotype is not perfect. Methods: We determined the linezolid MICs for clinical isolates from the Moscow region and identified mutations in rplC and rrl genes. Results: All 16 linezolid-resistant isolates had previously reported mutations in the rplC or rrl loci, and 13 of them bore a RplC C154R substitution. Detection of this substitution in a heteroresistant state was not successful, probably, due to the more stable DNA secondary structure of the mutated fragment, which precludes its amplification in mixes with the wild-type DNA. Strains with an rplC mutation had higher linezolid MIC compared to isolates with rrl mutations. Conclusions: Linezolid resistance mostly emerged during treatment with the latest regimen. Three primary cases with linezolid resistance question the possible transmission of totally drug-resistant tuberculosis in the Moscow region, which demands further investigation. View Full-Text
Keywords: tuberculosis; drug-resistance; linezolid tuberculosis; drug-resistance; linezolid
Show Figures

Figure 1

MDPI and ACS Style

Ushtanit, A.; Mikhailova, Y.; Lyubimova, A.; Makarova, M.; Safonova, S.; Filippov, A.; Borisov, S.; Zimenkov, D. Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow. Antibiotics 2021, 10, 1243. https://doi.org/10.3390/antibiotics10101243

AMA Style

Ushtanit A, Mikhailova Y, Lyubimova A, Makarova M, Safonova S, Filippov A, Borisov S, Zimenkov D. Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow. Antibiotics. 2021; 10(10):1243. https://doi.org/10.3390/antibiotics10101243

Chicago/Turabian Style

Ushtanit, Anastasia, Yulia Mikhailova, Alexandra Lyubimova, Marina Makarova, Svetlana Safonova, Alexey Filippov, Sergey Borisov, and Danila Zimenkov. 2021. "Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow" Antibiotics 10, no. 10: 1243. https://doi.org/10.3390/antibiotics10101243

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop